Brief Description
Stylus Medicine has created a new gene editing technology based on viral proteins called recombinases. These proteins naturally insert large swaths of DNA into bacterial genomes, but Stylus used machine learning to design recombinases that target specific regions of the human genome. The method is based on the pioneering work of Patrick Hsu, UC Berkeley assistant professor of bioengineering and co-founder and a core investigator of the Arc Institute. The company is on a mission to develop next-generation therapies for disease through genome engineering and chromatin regulation.
Timeline
- 2022. Company founded.
Inventor
Patrick David Hsu